Refine by
Drug Platform Articles & Analysis
154 news found
In an era where technological advancements are constantly reshaping the landscape of the pharmaceutical industry, Protheragen-ING has emerged as a frontrunner with its cutting-edge AI-synthesizer for small molecule drug synthesis. This revolutionary platform is transforming traditional drug formulation processes by employing a unique combination ...
The platform developed by Protheragen-ING AI-Pharma is a revolutionary step forward in the identification and optimization of drug candidates. ...
With customized delivery strategies, precise drug modifications, and advanced platforms, CD Bioparticles can streamline scientific research and development. ...
This platform allows for the controlled release of drugs over an extended period, providing patients with a consistent and steady supply of medication. By optimizing the release profile of drugs, this platform can improve patient compliance and reduce the risk of side effects associated with fluctuating drug ...
This technique allows for targeted drug delivery and controlled release, protecting the drug from degradation and enhancing its stability. Furthermore, CD Formulation specializes in nanoparticle development services for drug delivery systems. Nanoparticles, with their unique properties, can facilitate targeted drug delivery, ...
However, as with any medical product, it is crucial to assess the safety and potential toxicity of these novel drug delivery platforms. This is where CD Formulation steps in, providing state-of-the-art in vitro cytotoxicity testing for microspheres and microneedles. CD Formulation, a leader in the field of pharmaceutical formulation development, has been at the ...
CD Formulation, a reputable contract research organization (CRO) based in New York, has become a trusted partner for many pharmaceutical companies around the world seeking innovative drug formulation methods and solutions. Recently, CD Formulation further strengthened its role as a drug delivery expert by demonstrating its expertise in the development of ...
As part of its service portfolio, CD ComputaBio has launched the Computer Aided Drug Design (CADD) platform. This platform combines artificial intelligence and machine learning to streamline data processing, analysis, and model construction throughout the drug development process. Equipped with robust tools and algorithms, the ...
– a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. ...
The company plans to continue growing its team to power the expansion of Juvena’s drug discovery platform and advance the company’s biologics pipeline targeting chronic and age-related diseases. ...
VeriSIM Life has developed a whole-body biosimulation platform driven by AI and machine learning (ML), that accurately predicts the clinical efficacy of new drugs before human trials. We are delivering strategic insights from our platform to translate, scale, and accelerate drug development to advance human health. ...
About CTx-1301 Cingulate’s lead candidate, CTx-1301, utilizes the Company’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD. ...
The Flare™ structure-based and ligand-based drug design platform has a plugin interface that enables incorporation of cutting-edge third-party software (including OpenMM) to introduce new capabilities. ...
About Portal Instruments Portal Instruments is developing and commercializing a highly innovative needle-free drug delivery platform technology to transform the administration of medicines and improve the patient experience for chronic diseases. Portal’s needle-free delivery technology is derived from research at MIT and enables the administration of high ...
This preventative approach will allow Lumen to develop an inexpensive, biologic drug cocktail against the most frequent, multi-drug resistant infecting pathogens. ...
(NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. ...
(NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. ...
The appointment of former Merck, Sharp and Dohme (MSD) Director of R&D Analytics supports continued innovation of Optibrium’s AI drug discovery software Optibrium a leading developer of software and AI solutions for drug discovery, today announced the appointment of Ian Smith as Chief Technology Officer (CTO), the latest in a number of senior-level ...
About HemoShear Therapeutics HemoShear Therapeutics, Inc. is a privately held clinical stage company developing treatments for rare diseases with significant unmet patient need. HemoShear’s drug discovery platform, REVEAL-Tx™, enables the Company’s scientists to create best-in-class, biologically relevant human disease models to uncover the ...
The new funding will power the expansion of Juvena’s drug discovery platform and advance the company’s biologics pipeline targeting chronic and age-related diseases. ...